COMPARISON OF DISEASE SEVERITY AND IN-HOSPITAL OUTCOME OF COVID-19 AMONG NON-VACCINATED VERSUS VACCINATED (1ST DOSE) HOSPITALIZED PATIENTS IN A TERTIARY CARE HOSPITAL: AN OBSERVATIONAL STUDY

MAHBUB MAYUKH RISHAD1, ISHRAT BINTE REZA2,NAWSABAH NOOR1, TASMINA CHOWDHURY2, HOMAYRA TAHSIN2, MOHAMMAD ZAIRUDDIN3, QUAZI TARIKUL ISLAM3, H.A.M NAZMUL AHASAN3, KHAN ABUL KALAM AZAD5

Abstract:
Background: COVID-19 vaccines have a high rate of success in averting hospitalization and mortality. However, COVID-19 infection is still being detected among immunized patients, although with blunted severity. This study aimed to compare the severity and outcome of COVID-19 among immunized versus non-immunized individuals. Methods: This cross-sectional study was conducted over 179 COVID-19 patients in Popular Medical College Hospital, Dhaka. All the methods in the present study were carried out following the ethical guidelines of the 1975 Declaration of Helsinki. Data were collected from both hospital record and direct interview. Data were recorded in separated case record form and analyzed by STATA version 14. Results: Mean age of the study patients was 55.42±14.20 (SD) years wherein maximum were male (61.5%). Fever (88.8%), cough (81.6%), dyspnea (47.5%) and sore throat (30.2%) were most common symptoms. Maximum patients were hypertensive (60.9%) and diabetic (58.7%). About 35.8% of patients had mild severity, while 27.9% had moderate, 23.4% had severe, and 12.8% had critical stage. Maximum patients (n=122, 68.2%) were non-vaccinated and rest (n=57, 31.8%) had received 1st dose of vaccine. Vaccinated patients had significantly higher frequency of having mild COVID-19 (57.9% vs 31.1%, p<0.001) and getting discharge with full recovery (94.7% vs 76.2%, p=0.003) compared to non-vaccinated patients. Moreover, non-vaccinated patients were more prone to develop critical clinical syndrome (10.6% vs 1.8%, p=0.039) and had died or referred to higher center (11.4% vs 1.8%, p=0.029) than vaccinated individuals. Conclusion: COVID-19 vaccination was significantly associated with mild severity and lower rate of adverse outcome.

Keywords: COVID-19, Severity, Vaccination, Adverse outcome

Received: 16-06-2022 Accepted: 10-08-2022
DOI: https://doi.org/10.3329/bjm.v33i3.61376

Citation: Rishad MM, Reza IB, Naqsabah Noor, Chowdhury T, Tahseen H, Zahiruddin M et al. Comparison of Disease Severity and In-hospital Outcome of COVID-19 among Non-vaccinated versus Vaccinated (1st dose) Hospitalized Patients in a Tertiary Care Hospital: an Observational Study. Bangladesh J Medicine 2022; 33: 293-299.

1. Registrar of Medicine, Popular Medical College Hospital, Dhaka, Bangladesh
2. Assistant Professor of Medicine, Popular Medical College, Dhaka, Bangladesh
3. Assistant Professor of Medicine, Popular Medical College, Dhaka, Bangladesh
4. Associate Professor of Medicine, Popular Medical College, Dhaka, Bangladesh
5. Professor of Medicine, Popular Medical College, Dhaka, Bangladesh

Address of Correspondence: Dr. Mahbub Mayukh Rishad, Registrar of Medicine, Popular Medical College Hospital, Dhaka, Bangladesh. Email: mahbub.mayukh@gmail.com, Cell: +8801717246580,

Copyright: @ 2021 Associations of Physicians of Bangladesh
**Introduction:**

Since the beginning of COVID-19 infections, and its proclamation as a pandemic on March 11, 2020, the total 5,84,395 cases have been confirmed and 8,797 deaths have been recorded in Bangladesh, as of March 25, 2021.\(^1\) The infection rate and death toll had gradually climbed since the last week of March 2021, indicating the onset of the second wave of COVID-19.\(^2\) The sudden surge of cases might be caused by the newly identified SARS-CoV-2 double mutant Delta variant (B.1.617.2), which was wreaking havoc in India, UK, and other countries around the globe in recent months.\(^3\)

The main strategy to combat the COVID-19 infection is to stop the transmission in the community with preventive measures. Maintaining health protocols like frequent washing of hands, wearing a mask, maintaining social distance remains the main preventive attitude towards this disease. Yet, the vaccine has no alternative to mitigate the current pandemic situation. Worldwide, it is being taken seriously and responded to this rapidly for the development of vaccines against SARS-CoV-2, which have led to an unprecedented number of candidate vaccines starting clinical trials during 2020.\(^4\) Bangladesh received the Oxford AstraZeneca vaccine from Serum Institute of India, and started the mass vaccination program on 7 February 2021, with a focus primarily on high-risk groups such as the elderly, those with comorbidities, or front-line workers. Till March 25, 2021, total 51,39,456 people had received at least one dose of vaccine.\(^5\)

Unfortunately, several studies have reported the development of COVID-19 despite prior full vaccination throughout the world.\(^6\) Moreover, the delta version was shown to reduce the effectiveness of Oxford AstraZeneca vaccinations by 6.2 times when compared to the alpha variant.\(^7\) However, evaluations of COVID-19 vaccines have primarily focused on prevention of symptomatic infection and hospitalizations till date\(^8-11\), though effectiveness against progression of COVID-19 severity following breakthrough infection, must be taken into account when interpreting the protective benefits of COVID-19 vaccinations.\(^12\) SARS-CoV-2 infection in vaccinated persons is expected to trigger memory antibody and cellular responses owing to prior vaccination; these immune responses could mitigate disease progression, possibly preventing life-threatening organ failure and death.\(^13\) Surprisingly, there is still paucity of data regarding the association of prior vaccination and clinical outcome of COVID-19. Hence, this study was conducted to compare the disease severity and in-hospital outcome of COVID-19 among immunized versus non-immunized individuals.

**Methods:**

Descriptive observational study was performed in the COVID dedicated isolation wards/ cabins/ICU of Popular Medical College Hospital, a tertiary care center located in Dhaka, Bangladesh. The study data were collected between 1st April to 30th May 2021. All admitted COVID-19 patients diagnosed by reverse transcription polymerase chain reaction (RT-PCR) positivity were approached for this study. Patients who were not willing to include and had incomplete data were excluded from the study. Finally, a total of 179 patients were enrolled for data analysis. Data were collected from direct interview. A detailed history of clinical presentations, physical examinations, comorbidities, along with relevant investigations was also collected. Details of COVID-19 vaccination, including dates and location, vaccine product were ascertained. The severity assessment and management of the COVID-19 was done as per updated national guideline on clinical management of COVID-19.\(^14\) Patients were treated by the respective doctors of isolation wards/ cabines/ICU without any interference by the study physician for study purpose. The patients were followed up daily until discharge (with full recovery or on risk bond) and death. Adverse events were defined as death or referred to higher center due to disease deterioration. Study variables were demographic (age, gender, occupation, contact history, smoking history), clinical profile (symptom duration, clinical symptoms and comorbidities like hypertension, diabetes mellitus, obesity, asthma, chronic obstructive pulmonary disease, cardiac disease and renal disease), COVID-19 vaccination history, disease severity (mild, moderate, severe and critical) and in-hospital outcome (discharge with full recovery, referred to higher center, discharge on risk bond and death). The quality of the data was ensured by properly designing the tool and the questionnaire was pre-tested in randomly selected 20 cases before actual data collection, and some minor modifications were made accordingly. The principal investigator throughout the data collection process was in close contact and under close supervision. Data was collected in separated case record form. After collection of all the required data, data were checked, verified for consistency and entered into the STATA version 14. Association of vaccination status with disease severity and outcome was assessed by applying chi-square test taking a level of significance of <0.05 [Table-IV].

**Results:**

The average age of study population was 55.42±14.20 (SD) years wherein maximum (40.2%) were >60 years of age. Male was the predominant gender (61.5%) with a male:female ratio 1.6:1. Fifty-six (31.3%) patients had positive contact history with COVID-19 patients within last 14 days. Almost 1/3rd patients (n=57, 31.8%) had received at least one dose of vaccine and rest 122 (78.2%) patients were non-vaccinated. [Table-1]
Table-I
Socio-demographic profile of study population. (n=179)

| Variables                  | n (%)       |
|----------------------------|-------------|
| Mean±SD                    |             |
| Age (in years)             |             |
| 21-30                      | 10 (5.6)    |
| 31-40                      | 19 (12.8)   |
| 41-50                      | 30 (17.3)   |
| 51-60                      | 46 (24.0)   |
| >60                        | 74 (40.2)   |
| Gender                     |             |
| Male                       | 110 (61.5)  |
| Female                     | 69 (38.5)   |
| Occupation                 |             |
| Business                   | 58 (32.4)   |
| Service holder             | 8 (4.5)     |
| Doctor                     | 2 (1.1)     |
| Not employed               | 45 (25.1)   |
| House wife                 | 66 (36.9)   |
| Positive smoking history   | 12 (6.7)    |
| Positive COVID-19 contact history within last 14 days | 56 (31.3) |
| Vaccinated status          |             |
| Vaccinated (1st dose)      | 57 (31.8)   |
| Non-vaccinated             | 122 (68.2)  |

SD= Standard deviation

Maximum study patients (51.4%) admitted within 5 days of symptoms onset. The most common symptoms were fever (88.8%), cough (81.6%), dyspnea (47.5%) and sore throat (30.2%). Of all comorbidities, hypertension was on top (60.9%) followed by diabetes mellitus (58.7%), bronchial asthma (15.1%), chronic heart disease (8.9%), chronic kidney disease (7.3%) and chronic obstructive pulmonary disease (1.1%). Maximum study patients had mild COVID-19 illness (35.8%), while 27.9% had moderate, 23.4% had severe and 12.8% had critical clinical syndrome. [Table-II]

Majority COVID-19 patients were discharged with full recovery (n=149, 83.2%). Fifteen patients (8.4%) had adverse outcome, wherein 7 patients were referred to higher center and 8 patients had been expired. [Table-III]

Table-II
Disease profile of the study patients. (n=179)

| Variables                      | n (%)       |
|--------------------------------|-------------|
| Day of admission after symptom onset |             |
| 1-5 days                        | 92 (51.4)   |
| 6-10 days                       | 73 (40.8)   |
| >10 days                        | 14 (7.9)    |
| Clinical symptoms*              |             |
| Fever                           | 159 (88.8)  |
| Cough                           | 146 (81.6)  |
| Dyspnea                         | 85 (47.5)   |
| Sore throat                     | 54 (30.2)   |
| Diarrhoea                       | 25 (14.0)   |
| Fatigue                         | 21 (11.2)   |
| Altered taste                   | 21 (11.2)   |
| Chest pain                      | 17 (9.5)    |
| Headache                        | 13 (7.3)    |
| Vomiting                        | 11 (6.1)    |
| Conjunctivitis                  | 11 (6.1)    |
| Anorexia                        | 10 (5.6)    |
| Confusion                       | 10 (5.6)    |
| Nasal congestion                | 3 (1.7)     |
| Co-morbidities*                 |             |
| DM                              | 105 (58.7)  |
| HTN                             | 109 (60.9)  |
| Bronchial asthma                | 27 (15.1)   |
| COPD                            | 2 (1.1)     |
| CHD                             | 16 (8.9)    |
| CKD                             | 13 (7.3)    |
| Clinical severity               |             |
| Mild                            | 64 (35.8)   |
| Moderate                        | 50 (27.9)   |
| Severe                          | 42 (23.4)   |
| Critical                        | 23 (12.8)   |

*multiple response

DM= Diabetes mellitus, HTN=Hypertension, COPD=Chronic obstructive pulmonary disease, CHD=Chronic heart diseases, CKD=Chronic kidney disease

Table-III
In-hospital outcome of COVID-19 patients. (n=179)

| In-hospital outcome           | n (%)       |
|-------------------------------|-------------|
| Discharge                      |             |
| Discharged with full recovery | 149 (83.2)  |
| Discharge on risk bond         | 15 (7.8)    |
| Adverse events                 |             |
| Reference to higher center     | 7 (3.9)     |
| Death                          | 8 (4.5)     |
When compared to non-vaccinated patients, vaccinated patients had a significantly higher rate of mild severity (57.9% vs 31.1%, p<0.001) and discharge with full recovery (94.7% vs 76.2%, p=0.003). Furthermore, non-vaccinated patients were more likely to develop critical clinical syndrome (10.6% vs 1.8%, p=0.039) and to die or be referred to a higher center (11.4% vs 1.8%, p=0.029) than vaccinated patients. [Table-IV]

**Discussion:**
Coronavirus disease 2019 (COVID-19) can present with a variety of symptoms. The severity of the disease may be associated with several factors. Clinical trials of COVID-19 vaccines currently authorized for emergency use in the United States (Pfizer-BioNTech, Moderna, and Janssen-Johnson & Johnson) indicate that these vaccines have high efficacy against symptomatic disease, including moderate to severe illness. In the recently encountered second wave of COVID-19 from the last week of March 2021, we observed that people coming to the hospital as a case of Covid-19 even after getting the first shot of vaccination. Hence, this study was designed to compare the clinical outcome of COVID-19 among vaccinated (1st dose) and non-vaccinated hospitalized patients.

In this study, out of 179 COVID-19 patients, almost 1/3rd (n=57) patients were vaccinated (1st dose). This high rate is plausible as mass vaccination program started in Bangladesh on 7 February, less than two months earlier from our study period. Hence, maximum study patients hospitalized within less than 21 days of their vaccination. Studies proposed that during the first two to three weeks after the first dose of vaccination, efficacy is much lower than afterwards, as spike immunoglobulins G (IgG) begin to appear around this period. Besides, vaccine efficacy may be attenuated by antigen mutation (12), and it was during the study period that new variants (Delta variant) – possibly with antigen mutation – started to appear worldwide. This study found that vaccination has significant association with COVID-19 severity as vaccinated patients had significantly higher frequency of having mild disease, while non-vaccinated patients were more prone to develop critical clinical syndrome. Previous studies also illustrated that vaccinated individuals experienced a less severe form of the COVID-19 infection and less frequent hospitalization. In addition, a prospective cohort study by Thompson et al. concluded that COVID-19 vaccinated cases suffer lower duration of illness, and have lower risk of febrile symptoms. The mechanism, however; by which partial immunization attenuates the disease remains mostly unknown. This is possibly achieved through the vaccines’ ability to produce immunological memory responses, that hasten the removal of infected cells, while reducing viral replication. Indeed, several other studies also reported that influenza vaccination can lower COVID-19 severity.

Our study also revealed that vaccinated patients had significantly lower rate of adverse outcome (death or disease deterioration to refer in higher center). Besides, vaccinated individuals had higher frequency of getting discharge with full recovery compared to non-vaccinated patients. These results are also in accordance with the previous studies.

**Table-IV**

| Clinical outcome                        | Vaccination Status | p-value |
|----------------------------------------|--------------------|---------|
|                                        | Vaccinated (n=57)  | Non-vaccinated (n=122) |             |
|                                        | n (%)              | n (%)   |             |
| Clinical severity                      |                    |         |
| Mild                                   | 33 (57.9)          | 38 (31.1) | <0.001     |
| Moderate                               | 11 (19.2)          | 39 (31.9) | 0.078      |
| Severe                                 | 12 (19.3)          | 32 (26.2) | 0.454      |
| Critical                               | 1 (1.8)            | 13 (10.6) | 0.039      |
| In-hospital outcome                    |                    |         |
| Discharged with full recovery          | 54 (94.7)          | 93 (76.2) | 0.003      |
| Adverse events                         | 1 (1.8)            | 14 (11.4) | 0.029      |

p-value was determined by Pearson chi-square test. p-value<0.05 was considered as significant.
to our research design, Mhawish et al. observed that at least one dose of immunization lowers the adjusted odds of in-hospital mortality by 55%.18

The main baseline characteristics of our study were in accordance with studies from previous COVID-19 waves, as maximum study patients were older aged 28–32, male 33–35, hypertensive and diabetic.36–38

However, our study suffers numerous limitations. This was an observational study lacking the advantages of randomization. The sample size is relatively small and may have affected the power of the study. This was a single center study, reflecting the management of only one hospital. Also data on variants and impact on disease severity is lacking. And finally, our analysis lacks subdivision of immunized patients by duration since vaccination, which could have produced more informative results. On the other hand, the strengths of our work include the novelty of the topic, and identification of the under-reported problem pertinent to the population subjected to vaccination.

**Conclusion:**
In our study, the majority of COVID-19 patients were non-immunized, older aged, male, hypertensive and diabetic. Receiving at least one dose of immunization significantly decreases severity of the disease. Furthermore, at least one dose of immunization is significantly associated with lower adverse in-hospital outcome. Policy makers and clinicians may need to take the immunization status into consideration during management of COVID-19 patients.

**Supplementary Materials:** Available on request

**Funding:** This research received no external funding.

**Conflict of Interests:** None

**Ethical consideration:** Ethical measures were taken throughout the study period to maintain a high standard of confidentiality and anonymity of the participants. Formal approval was taken from the ethical review committee of Popular Medical College.

**Consent for Publication:** The authors agreed to publish the article by written consent.

**References:**

1. DGHS. COVID-19 Dynamic Dashboard for Bangladesh. 2021 [visited: 2021 Mar 25]. Available from: https://dghs-dashboard.com/pages/covid19.php

2. Bari R, Sultana F. Second Wave of COVID-19 in Bangladesh: An Integrated and Coordinated Set of Actions Is Crucial to Tackle Current Uprisings of Cases and Deaths. Front Public Heal. 2021;9. https://doi.org/10.3389/fpubh.2021.699918 PMid: 34527649 PMCid:PMC8437241

3. Bari MS, Hossain MJ, Akhter S, Emran TB. Delta variant and black fungal invasion: A bidirectional assault might worsen the massive second/third stream of COVID-19 outbreak in South-Asia. Ethics, Med public Heal. 2021 Dec;19:100722. https://doi.org/10.1016/j.jemep.2021.100722 PMID: 34514076 PMCid:PMC8416648

4. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med [Internet]. 2021;384(5):403-16. https://doi.org/10.1056/NEJMoa2035389 PMID:33378609 PMCid:PMC7787219

5. Coronavirus (COVID-19) Vaccinations. Our World in Data. 2021 [visited: 2021 Mar 25]. Available from: https://ourworldindata.org/covid-vaccinations?country=BGD

6. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep. 2021 May;70(19):972-3. https://doi.org/10.15585/mmwr.mm7021e3 PMID:34043615 PMCid:PMC8158893

7. Micocha P, Kemp S, Dhar MS, Papa G, Meng B, Mishra S, et al. SARS-CoV-2 B. 1. 617. 2 Delta variant emergence and vaccine breakthrough. 2021; https://doi.org/10.21203/rs.3.rs-637724/v1

8. Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J, et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med. 2021 Jul;385(4):320-9. https://doi.org/10.1056/NEJMc2113575

9. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Vol. 397, Lancet (London, England). 2021. p. 2461-2. https://doi.org/10.1016/S0140-6736(21)01358-1

10. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021;397(10286):1725-35. https://doi.org/10.1016/S0140-6736(21)00790-X

11. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162B2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med [Internet]. 2021 Apr 15;384(15):1412-23. https://doi.org/10.1056/NEJMoa2101765 PMID:33626250 PMCid:PMC7944975

12. Tenforde MW, Self WH, Adams K, Gagnani M, Ginde AA, McNeil T, et al. Association between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA - J Am Med Assoc. 2021;326(20):2043-54. https://doi.org/10.1001/jama.2021.19499 PMID:34734975 PMCid:PMC 8569602
Comparison of Disease Severity and In-hospital Outcome of COVID-19

13. Cromer D, Juno JA, Khoury D, Reynaldi A, Wheatley AK, Kent SJ, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol [Internet]. 2021;21(6):395-404. https://doi.org/10.1038/s41577-021-00550-x PMid:33927374 PMCid:PMC8082486

14. National Guidelines on Clinical Management of Coronavirus Disease 2019 ( COVID-19 ). Natl Guidel Clin Manag Coronavirus Dis 2019. 2020;4(March):1-28.

15. Nabavi S, Javidarabshahi Z, Allahyari A, Ramezani M, Seddigh-Shamsi M, Ravanshad S, et al. Clinical features and disease severity in an Iranian population of inpatients with COVID-19. Sci Rep. 2021;11(1):1-9. https://doi.org/10.1038/s41598-021-87917-1 PMid:33888747 PMCid:PMC8062510

16. Moline HL, Whitaker M, Deng L, Rhodes JC, Milucky J, Pham H, et al. Effectiveness of COVID-19 vaccines in preventing hospitalization among adults aged* 65 years-COVID-NET, 13 states, February-April 2021. Morb Mortal Wkly Rep. 2021;70(32):1088. https://doi.org/10.15585/mmwr.mm7032e3 PMid:34366759 PMCid:PMC8360274

17. Rzymksi P, Pazgan-Simon M, Simon K, Łapiński T, Zarębska-Michaluk D, Szczepańska B, et al. Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine. Vaccines. 2021 Jul;9(7). https://doi.org/10.3390/vaccines9070781 PMid:34581973 PMCid:PMC8310296

18. Mhawish H, Mady A, Alaklobi F, Aletreby W, Asad T, Alodat M, et al. Comparison of severity of unimmunized versus non-immunized COVID-19 patients admitted to ICU: A prospective observational study. Ann Med Surg. 2021 Nov;71:102951. https://doi.org/10.1016/j.amsu.2021.102951 PMid:34667593 PMCid:PMC8518130

19. Sanders RW, de Jong MD. Pandemic moves and countermoves: vaccines and viral variants. Lancet. 2021;397(10282):1326-7. https://doi.org/10.1016/S0140-6736(21)00730-3

20. Gul W, Samin KA, Ahmad R, Ullah K, Mehnaz G, Ahmed A. Comparison of Severity of Symptoms and Outcome among Vaccinated and Non-Vaccinated Covid 19 Patients in Khyber Pakhtunkhwa, Pakistan. Pakistan J Med Heal Sci. 2021;15(7):2334-7. https://doi.org/10.53350/pjmhs211572334

21. Selvaraj P, Muthu S, Jeyaraman N, Prajwal GS, Jeyaraman M. Incidence and severity of SARS-CoV-2 virus post COVID-19 vaccination: A cross-sectional study in India. Clin Epidemiol Glob Heal. 2022;14(December 2021):100983. https://doi.org/10.1016/j.cejgh.2022.100983 PMid:35155844 PMCid:PMC8824716

22. Abbasi J. COVID-19 mRNA vaccines blunt breakthrough infection severity. JAMA. 2021;326(6):473. https://doi.org/10.1001/jama.2021.12619

23. Fink G, Orlova-Fink N, Schindler T, Grisi S, Ferrer AP, Daubenberger C, et al. Inactivated trivalent influenza vaccine is associated with lower mortality among Covid-19 patients in Brazil. medRxiv 2020.06.29.20142505. https://doi.org/10.1101/2020.06.29.20142505

24. Huang K, Lin S-W, Sheng W-H, Wang C-C. Influenza vaccination and the risk of COVID-19 infection and severe illness in older adults in the United States. Sci Rep. 2021 May;11(1):11025. https://doi.org/10.1038/s41598-021-90068-y PMid:34040014 PMCid:PMC8155195

25. Wilcox CR, Islam N, Dambha-Miller H. Association between influenza vaccination and hospitalisation or all-cause mortality in people with COVID-19: a retrospective cohort study. BMJ open Respir Res. 2021;8(1):e000857. https://doi.org/10.1136/bmjresp-2020-000857. PMid:33664123 PMCid:PMC7934200

26. Macchia A, Ferrante D, Angeleri P, Biscayart C, Mariani J, Esteban S, et al. Evaluation of a COVID-19 Vaccine Campaign and SARS-CoV-2 Infection and Mortality Among Adults Aged 60 Years And Older in a Middle-Income Country. JAMA Netw Open [Internet]. 2021;4(10):e2130800-e2130800. https://doi.org/10.1001/jamanetworkopen.2021.30800. PMid:34714342 PMCid:PMC8556631

27. Huang Y-Z, Kuan C-C. Vaccination to reduce severe COVID-19 and mortality in COVID-19 patients: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2022 Mar;26(5):1770-6. https://doi.org/10.1136/jech-2020-214297. PMid:33681247 PMCid:PMC7298202

28. Khalatbari-Soltani S, Cumming RC, Delpierre C, Kelly-Irving M. Importance of collecting data on socioeconomic determinants from the early stage of the COVID-19 outbreak onwards. J Epidemiol Community Heal. 2020;74(8):620-3. https://doi.org/10.1136/jech-2020-214297. PMid:32385126 PMCid:PMC7298202

29. Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, et al. Aging in COVID-19: Vulnerability, immunity and intervention. Ageing Res Rev. 2021;65:101205. https://doi.org/10.1016/j.arr.2020.101205. PMid:33137510 PMCid:PMC7604159

30. Pijls BG, Jolani S, Atherley A, Derckx RT, Dijkstra NM, et al. Inactivated trivalent influenza vaccine is associated with lower mortality among COVID-19 patients in Brazil. medRxiv 2020.06.29.20142505. https://doi.org/10.1101/2020.06.29.20142505

31. Ikitimur H, Borku Uysal B, Cengiz M, Ikitimur B, Uysal H, Ozcan E, et al. Determining host factors
contributing to disease severity in a family cluster of 29 hospitalized SARS CoV 2 patients: Could genetic factors be relevant in the clinical course of COVID-19? J Med Virol. 2021;93(1):357-65. https://doi.org/10.1002/jmv.26106 PMid:32492209 PMCid:PMC7300487

32. Khamis F, Memish Z, Al Bahrani M, Al Dowaihi S, Pandak N, Al Bolushi Z, et al. Prevalence and predictors of in-hospital mortality of patients hospitalized with COVID-19 infection. J Infect Public Health. 2021;14(6):759-65. https://doi.org/10.1016/j.jiph.2021.03.016 PMid:34022734 PMCid:PMC8053361

33. Zhang N, Xie T, Ning W, He R, Zhu B, Mao Y. The severity of COVID-19 and its determinants: a systematic review and meta-analysis in China. Sustainability. 2021;13(9):5305. https://doi.org/10.3390/su13095305

34. Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588(7837):315-20. https://doi.org/10.1038/s41586-020-2700-3 PMid:32846427 PMCid:PMC7725931

35. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science (80- ). 2020;370(6515): eabd4585.

36. Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J renin-angiotensin-aldosterone Syst JRAAS. 2020;21(2). https://doi.org/10.1177/1470320320926899. PMid:32408793 PMCid:PMC7231906

37. Pal R, Bhadada SK. COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. Diabetes Metab Syndr Clin Res Rev. 2020;14(4):513-7. https://doi.org/10.1016/j.dsx.2020.04.049. PMid:32388331 PMCid:PMC7202837

38. Gregory JM, Slaughter JC, Duffus SH, Smith TJ, LeStourgeon LM, Jaser SS, et al. COVID-19 severity is tripled in the diabetes community: a prospective analysis of the pandemic’s impact in type 1 and type 2 diabetes. Diabetes Care. 2021;44(2):526-32. https://doi.org/10.2337/dc20-2260. PMid:33268335 PMCid:PMC7818316.